Altimmune (ALT) Current Assets (2010 - 2026)

Altimmune (ALT) has 17 years of Current Assets data on file, last reported at $334.7 million in Q1 2026.

• Current Assets for Q1 2026 came in at $334.7 million, up 115.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $334.7 million (up 115.56% YoY), and the FY2025 annual result was $278.2 million, up 102.68% from the prior year.
• Current Assets climbed to $334.7 million in Q1 2026 per ALT's latest filing, from $278.2 million in the prior quarter.
• Over five years, Current Assets peaked at $334.7 million in Q1 2026 and troughed at $137.3 million in Q4 2024.
• A 5-year average of $194.7 million and a median of $188.4 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2026: Current Assets plunged 34.52% in 2024, then jumped 115.56% in 2026.
• A 5-year view of Current Assets shows it stood at $192.8 million in 2022, then advanced by 8.72% to $209.6 million in 2023, then sank by 34.52% to $137.3 million in 2024, then soared by 102.68% to $278.2 million in 2025, then advanced by 20.3% to $334.7 million in 2026.
• Business Quant data shows ALT's Current Assets at $334.7 million in Q1 2026, $278.2 million in Q4 2025, and $216.6 million in Q3 2025.